Kornitzer Capital Management Inc. KS Sells 38,935 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Kornitzer Capital Management cut its stake in Lantheus by 49.1%, selling 38,935 shares and retaining 40,385 shares valued at about $2.69 million (0.06% ownership) in the fourth quarter.
• Lantheus beat expectations for the quarter with $1.67 EPS vs. $1.17 expected and $406.8M revenue vs. $367.0M expected, and issued FY2026 guidance of $5.00–$5.25 EPS.
• Analysts hold a consensus “Moderate Buy” on LNTH with a $88.86 target; the stock has a $5.57B market cap and a PE ratio of 25.37.

Kornitzer Capital Management Inc. KS lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 49.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 40,385 shares of the medical equipment provider's stock after selling 38,935 shares during the period. Kornitzer Capital Management Inc. KS owned 0.06% of Lantheus worth $2,688,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State of New Jersey Common Pension Fund D grew its holdings in Lantheus by 12.1% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 40,315 shares of the medical equipment provider's stock worth $2,683,000 after purchasing an additional 4,361 shares during the period. M&T Bank Corp bought a new position in Lantheus during the fourth quarter worth about $539,000. Ashton Thomas Private Wealth LLC grew its holdings in Lantheus by 1.8% during the fourth quarter. Ashton Thomas Private Wealth LLC now owns 21,700 shares of the medical equipment provider's stock worth $1,444,000 after purchasing an additional 388 shares during the period. Pictet Asset Management Holding SA boosted its holdings in shares of Lantheus by 8.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 10,658 shares of the medical equipment provider's stock worth $709,000 after acquiring an additional 867 shares during the period. Finally, Verdence Capital Advisors LLC boosted its holdings in shares of Lantheus by 3.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider's stock worth $563,000 after acquiring an additional 310 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Trading Up 1.0%

Shares of NASDAQ:LNTH opened at $85.50 on Friday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $108.91. The stock has a market cap of $5.57 billion, a PE ratio of 25.37 and a beta of -0.08. The business has a 50 day moving average of $78.85 and a 200-day moving average of $68.12. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts' expectations of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.29 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LNTH. Weiss Ratings upgraded Lantheus from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, January 6th. JonesTrading cut Lantheus from a "buy" rating to a "hold" rating in a report on Friday, February 27th. Mizuho boosted their price objective on Lantheus from $85.00 to $95.00 and gave the stock an "outperform" rating in a report on Monday, April 13th. Citizens Jmp boosted their price objective on Lantheus from $73.00 to $78.00 and gave the stock a "market outperform" rating in a report on Tuesday, February 24th. Finally, William Blair restated an "outperform" rating on shares of Lantheus in a report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $88.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.